Quartz·1 min read·medium
Bristol Myers Squibb is raising its full-year outlook after blood thinner sales surged past expectations
✦AI Summary
Bristol Myers Squibb raised its full-year outlook after reporting second-quarter revenue of $12.97 billion. The growth was driven by strong sales of its blood thinner Eliquis and newer pharmaceutical products.
Strong sales of blood thinner Eliquis and newer drugs Camzyos and Reblozyl pushed second-quarter revenue to $12.97 billion, above analyst estimates
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in